$HILS News
Last published 3y ago
- 3y agoHILSHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.ACCESS NewswireExpects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc.,
- 3y agoHILSHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisGlobeNewswireAnticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic
- 3y agoHILSHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13GlobeNewswireManagement will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream"
- 3y agoCIACWDDAKTFSTR+15Sidoti Events, LLC's Virtual August Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
- 3y agoHILSHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023GlobeNewswireManagement will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors
- 3y agoHILSHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215GlobeNewswireCollaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on "Knob" biologics (PicobodiesTM)
- 3y agoHILSHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsGlobeNewswireLead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary
- 3y agoHILSHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersGlobeNewswireAnti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against
- 3y agoHILSHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonGlobeNewswireBRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoATEXAYROBNETCODA+17Sidoti's Micro-Cap Virtual May ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 9, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023.
- 3y agoHILSHillstream BioPharma Announces Closing of Public Offering of Common StockGlobeNewswireBRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoHILSHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesGlobeNewswire12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C.
- 3y agoHILSHillstream BioPharma Announces Pricing of Public OfferingGlobeNewswireBRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoHILSHillstream BioPharma Announces Proposed Public OfferingGlobeNewswireBRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoHILSHillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer MechanismGlobeNewswireBRIDGEWATER, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoHILSHillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowACCESS NewswireBRIDGEWATER, NJ / ACCESSWIRE / April 12, 2023 / A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments.
- 3y agoHILSHillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical DataGlobeNewswireBRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates
- 3y agoHILSHillstream BioPharma to Participate in Two Major Industry Conferences in April 2023GlobeNewswireBRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug
- 3y agoHILSHillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023GlobeNewswireManagement will hold 1-on-1 meetings with institutional investors and analystsCompany recently signed an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license technology for HER2 and HER3
- 3y agoHILSHillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleGlobeNewswireCompany Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months Company's Novel
- 3y agoHILSHillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ETGlobeNewswireCompany's Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science
- 3y agoHILSHillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian CancerGlobeNewswireHER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast
- 3y agoHILSIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis InducerGlobeNewswireSynergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of cancer-related deaths worldwide NSCLC
- 3y agoHILSHillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & LeukemiasGlobeNewswirePreclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ/HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor) BRIDGEWATER, N.J., Feb. 08, 2023
- 3y agoHILSHillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant CancersGlobeNewswireQuatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers HSB-1940, an anti-PD-1 Quatrabody™, is a proprietary
- 3y agoHILSHillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersGlobeNewswireDevelopment expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung
- 3y agoHILSHillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023GlobeNewswireBRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an
- 3y agoHILSOABIHillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb's Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated TargetsGlobeNewswireCollaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived
- 3y agoHILSHillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022GlobeNewswireBRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an
- 4y agoHILSHillstream's New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR SymposiumGlobeNewswireBRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. ("Hillstream"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
- 4y agoHILSHillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20GlobeNewswireBRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism
- 4y agoHILSHillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13GlobeNewswireBRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism
- 4y agoHILSHillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer TreatmentsGlobeNewswireBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism
- 4y agoHILSHillstream BioPharma Announces Share Repurchase ProgramGlobeNewswireBRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism re
- 4y agoHILSHillstream BioPharma Provides Corporate UpdateGlobeNewswireRecent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent portfolio remain key competitive advantages Company ended Q1 2022 with $11 million in cash Pr
- 4y agoHILSHillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022GlobeNewswireDeveloped in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leaders Hillstream's presentation will feature its flagship treatment, HSB-1216, which
- 4y agoHILSHillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating CancersGlobeNewswireHSB-1216's active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomas HSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the FDA Rare Pediatric Disease (RPD) Designation and Orpha
- 4y agoHILSHillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal MelanomaGlobeNewswire-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell death, as a pathway to effectively eradicate uveal me
- 4y agoHILSHillstream BioPharma Provides Business Review with Key Pipeline UpdatesACCESS NewswireContinued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel Emerging Pipeline on February 24, 2022 BRIDGE
- 4y agoHILSSAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022ACCESS NewswireR&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments BRIDGEWATER, NJ / ACCESSWIRE / February 11, 2022 / Hi
- 4y agoHILSHillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc ExpressionACCESS NewswireBRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulti
- 4y agoHILSHillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic AtlasACCESS NewswireCollaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis / Iron Mediated Cell Death (IMCD) Pathways Furthe
- 4y agoHILSHillstream BioPharma Announces Closing of Initial Public OfferingACCESS NewswireBRIDGEWATER, NJ / ACCESSWIRE / January 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulti
- 4y agoHILSHillstream BioPharma Announces Pricing of Initial Public OfferingACCESS NewswireBRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulti